menu
    • menu
    [{"orgOrder":0,"company":"SRI International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"3,4,3-Li(1,2-hopo)","moa":"","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"SRI International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SRI International \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SRI International \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for 3,4,3-Li(1,2-hopo)

    Menu

    3,4,3-Li(1,2-hopo)

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SRI International

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            SRI International

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 3,4,3-Li(1,2-hopo)

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SRI’s Radioactive Contamination Treatment Is Now in Its First-In-Human Trial

                            Details : HOPO 14-1 (3,4,3-Li(1,2-hopo) is a novel orally administered experimental drug, designed to act as a defence against radioactive threats and is being investigated to treat radioactive contamination in the body.

                            Brand Name : HOPO 14-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 15, 2023

                            Lead Product(s) : 3,4,3-Li(1,2-hopo)

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth